Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,464 total articles

DT Midstream Publishes Annual Sustainability Report

DT Midstream Publishes Annual Sustainability Report

DT Midstream, a natural gas infrastructure company listed on the NYSE under ticker DTM, published its annual Corporate Sustainability Report detailing the company’s environmental, social, and governance accomplishments. The report emphasizes DT Midstream's commitment to sustainable operations and its role in safely delivering natural gas to key US …

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics announced the initiation of ASPEN-HCM, a prospective, multi-center real-world study assessing the safety, clinical effectiveness, and healthcare resource impact of MYQORZO (aficamten) in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The study is led by UCSF and plans to enroll approximately 400 patient…

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Biopharma Corporation has revealed preliminary results of its $230 million modified Dutch auction tender offer to repurchase up to 46 million shares at $5.00 per share. The tender offer was oversubscribed, leading to proration of shares purchased at about 55% for auction tenders at or below the purchase price. Roivant Sciences, a major shar…

Atlantic HPC Group Inc Acquires Valley Oasis Development LLC, Adding 29 MW of Contracted Power to Platform

Atlantic HPC Group Inc Acquires Valley Oasis Development LLC, Adding 29 MW of Contracted Power to Platform

Atlantic HPC Group Inc has acquired Valley Oasis Development LLC, a Tennessee-based entity holding contracts for 29 MW of utility power and a strategically located land lease suitable for bitcoin mining and AI compute deployments. This acquisition increases Atlantic's total utility-approved capacity to 127 MW across multiple states, strengthening i…

Green Circle Decarbonize Technology Limited Submits Tender Proposals for Chiller Replacement Engineering at MOS Centre and Air-Conditioning Retrofit & Operation and Maintenance at Nan Fung Centre in Hong Kong

Green Circle Decarbonize Technology Limited Submits Tender Proposals for Chiller Replacement Engineering at MOS Centre and Air-Conditioning Retrofit & Operation and Maintenance at Nan Fung Centre in Hong Kong

Green Circle Decarbonize Technology Limited, through its subsidiary Boca International Limited, has submitted two tender proposals worth a combined HKD 67 million for engineering projects involving chiller replacement and air-conditioning retrofit in key Hong Kong commercial centers. These projects emphasize energy efficiency, carbon emission reduc…

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Wave Life Sciences announced that GSK has selected a hepatology siRNA candidate developed using Wave's proprietary SpiNA design for further development in GSK's pipeline. This milestone triggers a $12 million payment to Wave, with potential for substantially more through future milestones and royalties. The collaboration includes three other progra…

Ocugen to Participate in Upcoming Scientific Conferences

Ocugen to Participate in Upcoming Scientific Conferences

Ocugen, Inc. announced its participation in several upcoming scientific conferences where it will present its novel modifier gene therapy platform targeting blindness diseases such as geographic atrophy, Stargardt disease, and retinitis pigmentosa. The company aims to demonstrate progress from multiple clinical trials including Phase 1/2 and Phase …

FactSet Reports Results for Fourth Quarter and Fiscal 2026

FactSet Reports Results for Fourth Quarter and Fiscal 2026

FactSet reported its fourth quarter and full fiscal 2026 financial results, highlighting a 7.0% increase in organic Annual Subscription Value (ASV), 6.7% revenue growth, and robust AI solution adoption which more than doubled year-over-year. The company maintained strong subscription retention and returned significant capital to shareholders throug…

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Satellos Bioscience Inc. announced the successful completion of enrollment for the BASECAMP Phase 2 clinical trial evaluating their oral small molecule drug candidate forazapadin for treating Duchenne muscular dystrophy (DMD) in ambulatory boys aged 7 to 10. The trial, conducted globally across multiple sites, will assess safety, tolerability, and …

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Kailera Therapeutics announced the completion of enrollment in its KaiNETIC global Phase 3 clinical program evaluating ribupatide injection, a dual GLP-1/GIP receptor agonist, for obesity treatment. The program includes three trials with topline data expected by mid-2028. Ribupatide aims to provide a once-weekly injectable treatment addressing unme…

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. has received FDA 510(k) clearance for new software updates to its Ceribell System that simplify interpretation of EEG data. These updates include features such as Alpha-Delta Ratio and Relative Alpha Trending, Burst Suppression monitoring, and Amplitude-Integrated EEG analysis, enabling faster and easier brain monitoring in critical …

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

NRx Pharmaceuticals' subsidiary, NRx Defense Systems, received an $11.18 million contract from DARPA to conduct the SPARC-TMS clinical trial evaluating a novel one-day robotic transcranial magnetic stimulation (TMS) protocol augmented with their investigational drug NRX-101 for treatment resistant depression. The trial, conducted at prestigious ins…

GDEV announces final results of previously announced self tender offer to purchase for cash up to $20,000,000 in value of its ordinary shares (or up to 1,813,236 Ordinary Shares) at a purchase price of $11.03 per ordinary share

GDEV announces final results of previously announced self tender offer to purchase for cash up to $20,000,000 in value of its ordinary shares (or up to 1,813,236 Ordinary Shares) at a purchase price of $11.03 per ordinary share

GDEV Inc. announced the final results of its cash tender offer to repurchase up to $20 million of its ordinary shares at $11.03 per share. Only 57,110 shares (approximately 0.3% of total shares) were tendered and purchased, costing about $630,000. The repurchased shares will be held as treasury stock for potential future issuance. This buyback repr…

Ambow Launches HybriU Events On Demand, Bringing AI-Powered Hybrid Events to Venues in a Single Transport Case

Ambow Launches HybriU Events On Demand, Bringing AI-Powered Hybrid Events to Venues in a Single Transport Case

Ambow Education Holding Ltd. (NYSE American: AMBO) has introduced HybriU Events On Demand, a portable, AI-driven hybrid event system delivered in a single transport case, enabling venues to host professional 2D/3D live broadcasts, real-time interpretation in 65+ languages, recording, and AI knowledge capture without permanent installation or equipm…

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC). While the primary endpoint did not reach statistical significance in the overall population, a prespecified subgroup receiving background miglustat and/or leucine therapy (83% of patients) showed …

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

Tiziana Life Sciences announced the submission of an Orphan Drug Designation request to the FDA for intranasal foralumab, an immunomodulatory therapy aimed at treating Multiple System Atrophy (MSA). This designation would provide regulatory benefits including market exclusivity and tax credits, supporting advancement of this novel treatment. The co…

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals announced the presentation of new data from its Phase 4 SYNCHRONICITY trial on Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis at the American Academy of Ophthalmology 2026 meeting. The data include six-month topline results and post-hoc analyses from the NEW DAY trial for diabetic macular edema. T…